Roberts C J, Jackson L, Halliwell M, Branch R A
Br J Clin Pharmacol. 1976 Oct;3(5):907-13. doi: 10.1111/j.1365-2125.1976.tb00646.x.
Liver volume and the clearances of antipyrine and indocyanine green have been measured before and after administration of phenobarbitone (180 mg/day) for 3 weeks to ten healthy subjects. The measurement of liver volume by an ultrasound scanning technique yielded reproducible results which were consistent with predictions of liver size by allometric methods. Before phenobarbitone, antipyrine clearance correlated with liver volume, but there was no correlation between indocyanine green clearance and liver volume. Phenobarbitone administration increased the clearance of antipyrine significantly by 90 +/- 14% but there was no significant change in indocyanine green clearance or liver volume. After phenobarbitone the correlation between antipyrine clearance and liver volume persisted. There was no correlation between indocyanine green clearance and liver volume. These results suggest that in non-medicated subjects some of the difference in antipyrine clearance is due to difference in functional hepatic parenchymal mass and that phenobarbitone increases the drug metabolising capacity per unit of hepatic mass but not total liver size.
对10名健康受试者在服用苯巴比妥(180毫克/天)3周前后测量了肝脏体积以及安替比林和吲哚菁绿的清除率。通过超声扫描技术测量肝脏体积得到了可重复的结果,这些结果与根据体视学方法对肝脏大小的预测一致。在服用苯巴比妥之前,安替比林清除率与肝脏体积相关,但吲哚菁绿清除率与肝脏体积之间无相关性。服用苯巴比妥使安替比林清除率显著增加了90±14%,但吲哚菁绿清除率或肝脏体积无显著变化。服用苯巴比妥后,安替比林清除率与肝脏体积之间的相关性依然存在。吲哚菁绿清除率与肝脏体积之间无相关性。这些结果表明,在未用药的受试者中,安替比林清除率的一些差异是由于功能性肝实质质量的差异所致,并且苯巴比妥增加了每单位肝脏质量的药物代谢能力,但未增加肝脏的总体大小。